Literature DB >> 1306684

Interaction of heparin-binding EGF-like growth factor (HB-EGF) with the epidermal growth factor receptor: modulation by heparin, heparinase, or synthetic heparin-binding HB-EGF fragments.

G E Besner1, D Whelton, M A Crissman-Combs, C L Steffen, G Y Kim, D R Brigstock.   

Abstract

The binding of heparin-binding EGF-like growth factor (HB-EGF) to the epidermal growth factor (EGF) receptor of human endometrial carcinoma cells was compared to that of EGF using an 125I-EGF radioreceptor assay. The inhibitory effect of HB-EGF on 125I-EGF binding was reversed either in the presence of heparin (but not by chondroitin sulfate) or by pre-treating the cells with heparinase. These treatments did not affect the binding of EGF to its receptor. To map potential regions in the HB-EGF molecule that mediate its heparin-dependent interaction with the EGF receptor, HB-EGF peptides were synthesized that were non-homologous to EGF. Accordingly residues 20-25 and 36-41, but not residues 8-19, of HB-EGF were found to be (i) heparin-binding and (ii) modulators of HB-EGF (but not of EGF) binding to the EGF receptor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1306684     DOI: 10.3109/08977199209046411

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  10 in total

1.  Receptor-based antidote for diphtheria.

Authors:  Jeong-Heon Cha; Joanna S Brooke; Mee Young Chang; Leon Eidels
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

2.  Immunohistochemical localization of heparin-binding epidermal growth factor-like growth factor in normal skin and skin cancers.

Authors:  M T Downing; D R Brigstock; M H Luquette; M Crissman-Combs; G E Besner
Journal:  Histochem J       Date:  1997-10

3.  Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF.

Authors:  D Aviezer; A Yayon
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

4.  Epidermal growth factor-like molecular species in normal bronchoalveolar lavage fluid.

Authors:  R K Kumar; R O'Grady; N Di Girolamo
Journal:  Lung       Date:  1996       Impact factor: 2.584

5.  Protease-mediated human smooth muscle cell proliferation by urokinase requires epidermal growth factor receptor transactivation by triple membrane signaling.

Authors:  Enrico A Duru; Yuyang Fu; Mark G Davies
Journal:  J Surg Res       Date:  2014-07-02       Impact factor: 2.192

6.  Heparin-binding epidermal growth factor-like growth factor in hippocampus: modulation of expression by seizures and anti-excitotoxic action.

Authors:  L A Opanashuk; R J Mark; J Porter; D Damm; M P Mattson; K B Seroogy
Journal:  J Neurosci       Date:  1999-01-01       Impact factor: 6.167

7.  Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediated mechanism.

Authors:  Andrew M Bakken; Clinton D Protack; Elisa Roztocil; Suzanne M Nicholl; Mark G Davies
Journal:  J Vasc Surg       Date:  2009-05       Impact factor: 4.268

8.  The metalloendopeptidase nardilysin (NRDc) is potently inhibited by heparin-binding epidermal growth factor-like growth factor (HB-EGF).

Authors:  Véronique Hospital; Eiichiro Nishi; Michael Klagsbrun; Paul Cohen; Nabil G Seidah; Annik Prat
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

9.  Insulin-induced epidermal growth factor activation in vascular smooth muscle cells is ADAM-dependent.

Authors:  Elisa Roztocil; Suzanne M Nicholl; Mark G Davies
Journal:  Surgery       Date:  2008-05-27       Impact factor: 3.982

10.  Removal of the membrane-anchoring domain of epidermal growth factor leads to intracrine signaling and disruption of mammary epithelial cell organization.

Authors:  H S Wiley; M F Woolf; L K Opresko; P M Burke; B Will; J R Morgan; D A Lauffenburger
Journal:  J Cell Biol       Date:  1998-11-30       Impact factor: 10.539

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.